nodes	percent_of_prediction	percent_of_DWPC	metapath
Mitoxantrone—Topoisomerase Inhibitors—Etoposide—sarcoma	0.286	0.43	CiPCiCtD
Mitoxantrone—Topoisomerase Inhibitors—Epirubicin—sarcoma	0.197	0.296	CiPCiCtD
Mitoxantrone—Topoisomerase Inhibitors—Doxorubicin—sarcoma	0.182	0.274	CiPCiCtD
Mitoxantrone—TOP2A—Epirubicin—sarcoma	0.0293	0.124	CbGbCtD
Mitoxantrone—TOP2A—Etoposide—sarcoma	0.0228	0.0966	CbGbCtD
Mitoxantrone—ABCC1—Dactinomycin—sarcoma	0.0224	0.0949	CbGbCtD
Mitoxantrone—ABCC1—Epirubicin—sarcoma	0.0162	0.0688	CbGbCtD
Mitoxantrone—TOP2A—Doxorubicin—sarcoma	0.0156	0.0659	CbGbCtD
Mitoxantrone—ABCG2—Dactinomycin—sarcoma	0.015	0.0635	CbGbCtD
Mitoxantrone—ABCC1—Vincristine—sarcoma	0.0138	0.0585	CbGbCtD
Mitoxantrone—ABCC1—Etoposide—sarcoma	0.0126	0.0536	CbGbCtD
Mitoxantrone—CYP2E1—Dacarbazine—sarcoma	0.0123	0.0522	CbGbCtD
Mitoxantrone—CYP1B1—Doxorubicin—sarcoma	0.0121	0.0514	CbGbCtD
Mitoxantrone—ABCG2—Vincristine—sarcoma	0.00923	0.0391	CbGbCtD
Mitoxantrone—ABCC1—Doxorubicin—sarcoma	0.00862	0.0365	CbGbCtD
Mitoxantrone—ABCG2—Etoposide—sarcoma	0.00846	0.0358	CbGbCtD
Mitoxantrone—CYP3A4—Thiotepa—sarcoma	0.00674	0.0286	CbGbCtD
Mitoxantrone—CYP2E1—Etoposide—sarcoma	0.00603	0.0256	CbGbCtD
Mitoxantrone—ABCG2—Doxorubicin—sarcoma	0.00577	0.0245	CbGbCtD
Mitoxantrone—ABCB1—Dactinomycin—sarcoma	0.0054	0.0229	CbGbCtD
Mitoxantrone—ABCB1—Vincristine—sarcoma	0.00333	0.0141	CbGbCtD
Mitoxantrone—ABCB1—Etoposide—sarcoma	0.00305	0.0129	CbGbCtD
Mitoxantrone—ABCB1—Doxorubicin—sarcoma	0.00208	0.00882	CbGbCtD
Mitoxantrone—CYP3A4—Vincristine—sarcoma	0.00199	0.00845	CbGbCtD
Mitoxantrone—CYP3A4—Etoposide—sarcoma	0.00183	0.00774	CbGbCtD
Mitoxantrone—CYP3A4—Doxorubicin—sarcoma	0.00125	0.00528	CbGbCtD
Mitoxantrone—PIM1—mammary gland—sarcoma	0.000911	0.046	CbGeAlD
Mitoxantrone—BTK—myometrium—sarcoma	0.000746	0.0377	CbGeAlD
Mitoxantrone—PIM1—myometrium—sarcoma	0.000646	0.0327	CbGeAlD
Mitoxantrone—BTK—hematopoietic system—sarcoma	0.000641	0.0324	CbGeAlD
Mitoxantrone—BTK—connective tissue—sarcoma	0.000617	0.0312	CbGeAlD
Mitoxantrone—PIM1—seminal vesicle—sarcoma	0.000584	0.0295	CbGeAlD
Mitoxantrone—SLC47A2—tendon—sarcoma	0.000562	0.0284	CbGeAlD
Mitoxantrone—PIM1—hematopoietic system—sarcoma	0.000555	0.028	CbGeAlD
Mitoxantrone—PIM1—connective tissue—sarcoma	0.000534	0.027	CbGeAlD
Mitoxantrone—PIM1—skin of body—sarcoma	0.000482	0.0244	CbGeAlD
Mitoxantrone—BTK—lymphoid tissue—sarcoma	0.000451	0.0228	CbGeAlD
Mitoxantrone—BTK—tendon—sarcoma	0.000424	0.0214	CbGeAlD
Mitoxantrone—PIM1—cardiac atrium—sarcoma	0.000421	0.0213	CbGeAlD
Mitoxantrone—PIM1—uterus—sarcoma	0.000419	0.0212	CbGeAlD
Mitoxantrone—BTK—bone marrow—sarcoma	0.000411	0.0208	CbGeAlD
Mitoxantrone—PIM1—lymphoid tissue—sarcoma	0.000391	0.0197	CbGeAlD
Mitoxantrone—TOP2A—myometrium—sarcoma	0.000379	0.0192	CbGeAlD
Mitoxantrone—PIM1—tendon—sarcoma	0.000367	0.0186	CbGeAlD
Mitoxantrone—CYP1B1—mammary gland—sarcoma	0.000358	0.0181	CbGeAlD
Mitoxantrone—PIM1—bone marrow—sarcoma	0.000356	0.018	CbGeAlD
Mitoxantrone—BTK—testis—sarcoma	0.000351	0.0177	CbGeAlD
Mitoxantrone—SLC47A1—myometrium—sarcoma	0.000346	0.0175	CbGeAlD
Mitoxantrone—BTK—liver—sarcoma	0.000332	0.0168	CbGeAlD
Mitoxantrone—SLC47A1—seminal vesicle—sarcoma	0.000313	0.0158	CbGeAlD
Mitoxantrone—PIM1—testis—sarcoma	0.000304	0.0154	CbGeAlD
Mitoxantrone—SLC47A1—hematopoietic system—sarcoma	0.000297	0.015	CbGeAlD
Mitoxantrone—PIM1—liver—sarcoma	0.000287	0.0145	CbGeAlD
Mitoxantrone—BTK—lymph node—sarcoma	0.000254	0.0129	CbGeAlD
Mitoxantrone—TOP2A—Vindesine—Vincristine—sarcoma	0.000252	0.191	CbGdCrCtD
Mitoxantrone—TOP2A—uterus—sarcoma	0.000246	0.0124	CbGeAlD
Mitoxantrone—ABCC1—myometrium—sarcoma	0.000228	0.0115	CbGeAlD
Mitoxantrone—SLC47A1—uterus—sarcoma	0.000225	0.0113	CbGeAlD
Mitoxantrone—PIM1—lymph node—sarcoma	0.00022	0.0111	CbGeAlD
Mitoxantrone—CYP1B1—hematopoietic system—sarcoma	0.000218	0.011	CbGeAlD
Mitoxantrone—TOP2A—tendon—sarcoma	0.000215	0.0109	CbGeAlD
Mitoxantrone—CYP1B1—connective tissue—sarcoma	0.00021	0.0106	CbGeAlD
Mitoxantrone—TOP2A—bone marrow—sarcoma	0.000209	0.0105	CbGeAlD
Mitoxantrone—ABCC1—seminal vesicle—sarcoma	0.000206	0.0104	CbGeAlD
Mitoxantrone—SLC47A1—tendon—sarcoma	0.000197	0.00994	CbGeAlD
Mitoxantrone—CYP1B1—smooth muscle tissue—sarcoma	0.000192	0.0097	CbGeAlD
Mitoxantrone—CYP1B1—skin of body—sarcoma	0.000189	0.00957	CbGeAlD
Mitoxantrone—ABCG2—myometrium—sarcoma	0.000189	0.00955	CbGeAlD
Mitoxantrone—TOP2A—testis—sarcoma	0.000178	0.00901	CbGeAlD
Mitoxantrone—ABCG2—seminal vesicle—sarcoma	0.000171	0.00863	CbGeAlD
Mitoxantrone—CYP1B1—uterus—sarcoma	0.000165	0.00832	CbGeAlD
Mitoxantrone—SLC47A1—testis—sarcoma	0.000163	0.00823	CbGeAlD
Mitoxantrone—TOP2A—Vinorelbine—Vincristine—sarcoma	0.000159	0.121	CbGdCrCtD
Mitoxantrone—TOP2A—Teniposide—Etoposide—sarcoma	0.000159	0.121	CbGdCrCtD
Mitoxantrone—TOP2A—Podofilox—Etoposide—sarcoma	0.000159	0.121	CbGdCrCtD
Mitoxantrone—SLC47A1—liver—sarcoma	0.000154	0.00778	CbGeAlD
Mitoxantrone—CYP1B1—lymphoid tissue—sarcoma	0.000153	0.00775	CbGeAlD
Mitoxantrone—ABCC1—cardiac atrium—sarcoma	0.000149	0.00752	CbGeAlD
Mitoxantrone—ABCC1—uterus—sarcoma	0.000148	0.00748	CbGeAlD
Mitoxantrone—CYP2E1—seminal vesicle—sarcoma	0.000148	0.00747	CbGeAlD
Mitoxantrone—CYP1B1—tendon—sarcoma	0.000144	0.00729	CbGeAlD
Mitoxantrone—CYP2E1—hematopoietic system—sarcoma	0.00014	0.0071	CbGeAlD
Mitoxantrone—ABCC1—tendon—sarcoma	0.00013	0.00655	CbGeAlD
Mitoxantrone—TOP2A—lymph node—sarcoma	0.000129	0.00653	CbGeAlD
Mitoxantrone—ABCG2—uterus—sarcoma	0.000123	0.00619	CbGeAlD
Mitoxantrone—CYP1B1—testis—sarcoma	0.000119	0.00603	CbGeAlD
Mitoxantrone—SLC47A1—lymph node—sarcoma	0.000118	0.00597	CbGeAlD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—PLCG1—sarcoma	0.000118	0.00428	CbGpPWpGaD
Mitoxantrone—BTK—Class I PI3K signaling events—SRC—sarcoma	0.000117	0.00425	CbGpPWpGaD
Mitoxantrone—BTK—IL-5 Signaling Pathway—MYC—sarcoma	0.000115	0.00419	CbGpPWpGaD
Mitoxantrone—TOP2A—Gastric Cancer Network 2—CTNNB1—sarcoma	0.000113	0.00412	CbGpPWpGaD
Mitoxantrone—BTK—TSLP Signaling Pathway—SRC—sarcoma	0.000113	0.00411	CbGpPWpGaD
Mitoxantrone—CYP3A4—hematopoietic system—sarcoma	0.000113	0.00571	CbGeAlD
Mitoxantrone—CYP1B1—liver—sarcoma	0.000113	0.0057	CbGeAlD
Mitoxantrone—BTK—Class I PI3K signaling events—NRAS—sarcoma	0.000113	0.00409	CbGpPWpGaD
Mitoxantrone—PIM1—C-MYB transcription factor network—KRAS—sarcoma	0.000109	0.00397	CbGpPWpGaD
Mitoxantrone—TOP2A—Vinblastine—Vincristine—sarcoma	0.000109	0.083	CbGdCrCtD
Mitoxantrone—BTK—B Cell Activation—PLCG1—sarcoma	0.000109	0.00397	CbGpPWpGaD
Mitoxantrone—BTK—EPO signaling pathway—HRAS—sarcoma	0.000108	0.00393	CbGpPWpGaD
Mitoxantrone—ABCC1—testis—sarcoma	0.000107	0.00543	CbGeAlD
Mitoxantrone—BTK—IL-5 Signaling Pathway—KRAS—sarcoma	0.000107	0.00387	CbGpPWpGaD
Mitoxantrone—ABCG2—bone marrow—sarcoma	0.000104	0.00526	CbGeAlD
Mitoxantrone—ABCG2—HIF-2-alpha transcription factor network—KDR—sarcoma	0.000103	0.00373	CbGpPWpGaD
Mitoxantrone—BTK—Fc-epsilon receptor I signaling in mast cells—JUN—sarcoma	0.000102	0.00372	CbGpPWpGaD
Mitoxantrone—ABCC1—S1P1 pathway—VEGFA—sarcoma	0.000102	0.00372	CbGpPWpGaD
Mitoxantrone—PIM1—Validated targets of C-MYC transcriptional activation—TP53—sarcoma	0.000102	0.0037	CbGpPWpGaD
Mitoxantrone—ABCC1—liver—sarcoma	0.000102	0.00513	CbGeAlD
Mitoxantrone—BTK—TSLP Signaling Pathway—MYC—sarcoma	0.000101	0.00368	CbGpPWpGaD
Mitoxantrone—BTK—MyD88:Mal cascade initiated on plasma membrane—CREB1—sarcoma	0.000101	0.00366	CbGpPWpGaD
Mitoxantrone—CYP2E1—lymphoid tissue—sarcoma	9.89e-05	0.005	CbGeAlD
Mitoxantrone—ABCG2—HIF-1-alpha transcription factor network—CXCR4—sarcoma	9.88e-05	0.00359	CbGpPWpGaD
Mitoxantrone—BTK—B Cell Receptor Signaling Pathway—CREB1—sarcoma	9.82e-05	0.00357	CbGpPWpGaD
Mitoxantrone—PIM1—Ectoderm Differentiation—CTNNB1—sarcoma	9.81e-05	0.00356	CbGpPWpGaD
Mitoxantrone—BTK—Class I PI3K signaling events—KRAS—sarcoma	9.7e-05	0.00352	CbGpPWpGaD
Mitoxantrone—BTK—BCR signaling pathway—JUN—sarcoma	9.49e-05	0.00345	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	9.48e-05	0.00344	CbGpPWpGaD
Mitoxantrone—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—MDM2—sarcoma	9.43e-05	0.00343	CbGpPWpGaD
Mitoxantrone—BTK—Kit receptor signaling pathway—SRC—sarcoma	9.43e-05	0.00343	CbGpPWpGaD
Mitoxantrone—ABCB1—myometrium—sarcoma	9.32e-05	0.00471	CbGeAlD
Mitoxantrone—CYP2E1—tendon—sarcoma	9.3e-05	0.0047	CbGeAlD
Mitoxantrone—PIM1—C-MYB transcription factor network—HRAS—sarcoma	9.28e-05	0.00337	CbGpPWpGaD
Mitoxantrone—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRB—sarcoma	9.24e-05	0.00336	CbGpPWpGaD
Mitoxantrone—TOP2A—Gastric Cancer Network 2—MYC—sarcoma	9.19e-05	0.00334	CbGpPWpGaD
Mitoxantrone—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRA—sarcoma	9.1e-05	0.00331	CbGpPWpGaD
Mitoxantrone—TOP2A—Gastric Cancer Network 2—EGFR—sarcoma	8.99e-05	0.00327	CbGpPWpGaD
Mitoxantrone—ABCB1—embryo—sarcoma	8.96e-05	0.00453	CbGeAlD
Mitoxantrone—BTK—DAP12 signaling—FOXO1—sarcoma	8.89e-05	0.00323	CbGpPWpGaD
Mitoxantrone—ABCG2—testis—sarcoma	8.89e-05	0.00449	CbGeAlD
Mitoxantrone—BTK—DAP12 signaling—PDGFRB—sarcoma	8.88e-05	0.00323	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 signaling—PDGFRA—sarcoma	8.74e-05	0.00318	CbGpPWpGaD
Mitoxantrone—BTK—Activated TLR4 signalling—CREB1—sarcoma	8.69e-05	0.00316	CbGpPWpGaD
Mitoxantrone—CYP1B1—lymph node—sarcoma	8.66e-05	0.00437	CbGeAlD
Mitoxantrone—ABCB1—seminal vesicle—sarcoma	8.42e-05	0.00425	CbGeAlD
Mitoxantrone—ABCG2—liver—sarcoma	8.41e-05	0.00425	CbGeAlD
Mitoxantrone—BTK—DAP12 interactions—FOXO1—sarcoma	8.37e-05	0.00304	CbGpPWpGaD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—FOXO1—sarcoma	8.37e-05	0.00304	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 interactions—PDGFRB—sarcoma	8.35e-05	0.00303	CbGpPWpGaD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—PDGFRB—sarcoma	8.35e-05	0.00303	CbGpPWpGaD
Mitoxantrone—TOP2A—Idarubicin—Epirubicin—sarcoma	8.27e-05	0.0629	CbGdCrCtD
Mitoxantrone—TOP2A—Daunorubicin—Epirubicin—sarcoma	8.27e-05	0.0629	CbGdCrCtD
Mitoxantrone—TOP2A—Doxorubicin—Epirubicin—sarcoma	8.27e-05	0.0629	CbGdCrCtD
Mitoxantrone—BTK—Class I PI3K signaling events—HRAS—sarcoma	8.24e-05	0.00299	CbGpPWpGaD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—PDGFRA—sarcoma	8.22e-05	0.00299	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 interactions—PDGFRA—sarcoma	8.22e-05	0.00299	CbGpPWpGaD
Mitoxantrone—BTK—Toll Like Receptor 4 (TLR4) Cascade—CREB1—sarcoma	8.17e-05	0.00297	CbGpPWpGaD
Mitoxantrone—ABCB1—hematopoietic system—sarcoma	8e-05	0.00404	CbGeAlD
Mitoxantrone—PIM1—Ectoderm Differentiation—MYC—sarcoma	7.94e-05	0.00289	CbGpPWpGaD
Mitoxantrone—ABCC1—lymph node—sarcoma	7.79e-05	0.00393	CbGeAlD
Mitoxantrone—BTK—B Cell Activation—FOXO1—sarcoma	7.74e-05	0.00281	CbGpPWpGaD
Mitoxantrone—BTK—B Cell Activation—PDGFRB—sarcoma	7.73e-05	0.00281	CbGpPWpGaD
Mitoxantrone—CYP2E1—testis—sarcoma	7.7e-05	0.00389	CbGeAlD
Mitoxantrone—TOP2A—Idarubicin—Doxorubicin—sarcoma	7.65e-05	0.0582	CbGdCrCtD
Mitoxantrone—TOP2A—Epirubicin—Doxorubicin—sarcoma	7.65e-05	0.0582	CbGdCrCtD
Mitoxantrone—TOP2A—Daunorubicin—Doxorubicin—sarcoma	7.65e-05	0.0582	CbGdCrCtD
Mitoxantrone—BTK—B Cell Activation—PDGFRA—sarcoma	7.61e-05	0.00276	CbGpPWpGaD
Mitoxantrone—ABCB1—HIF-1-alpha transcription factor network—NPM1—sarcoma	7.56e-05	0.00275	CbGpPWpGaD
Mitoxantrone—TOP2A—Gastric Cancer Network 2—TP53—sarcoma	7.55e-05	0.00274	CbGpPWpGaD
Mitoxantrone—BTK—Fcgamma receptor (FCGR) dependent phagocytosis—SRC—sarcoma	7.32e-05	0.00266	CbGpPWpGaD
Mitoxantrone—BTK—Toll-Like Receptors Cascades—CREB1—sarcoma	7.28e-05	0.00264	CbGpPWpGaD
Mitoxantrone—CYP2E1—liver—sarcoma	7.28e-05	0.00368	CbGeAlD
Mitoxantrone—BTK—MyD88:Mal cascade initiated on plasma membrane—JUN—sarcoma	7.24e-05	0.00263	CbGpPWpGaD
Mitoxantrone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—FLT1—sarcoma	7.18e-05	0.00261	CbGpPWpGaD
Mitoxantrone—BTK—B Cell Receptor Signaling Pathway—JUN—sarcoma	7.06e-05	0.00257	CbGpPWpGaD
Mitoxantrone—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—sarcoma	7.05e-05	0.00256	CbGpPWpGaD
Mitoxantrone—ABCB1—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	7.04e-05	0.00256	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 signaling—KIT—sarcoma	6.78e-05	0.00246	CbGpPWpGaD
Mitoxantrone—BTK—Kit receptor signaling pathway—HRAS—sarcoma	6.64e-05	0.00241	CbGpPWpGaD
Mitoxantrone—BTK—Fc-epsilon receptor I signaling in mast cells—HRAS—sarcoma	6.46e-05	0.00235	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 signaling—CREB1—sarcoma	6.45e-05	0.00234	CbGpPWpGaD
Mitoxantrone—Cardiac failure—Epirubicin—sarcoma	6.45e-05	0.00126	CcSEcCtD
Mitoxantrone—ABCG2—lymph node—sarcoma	6.45e-05	0.00326	CbGeAlD
Mitoxantrone—CYP1B1—Tryptophan metabolism—MDM2—sarcoma	6.42e-05	0.00233	CbGpPWpGaD
Mitoxantrone—Cardiac failure congestive—Doxorubicin—sarcoma	6.42e-05	0.00125	CcSEcCtD
Mitoxantrone—BTK—DAP12 interactions—KIT—sarcoma	6.38e-05	0.00232	CbGpPWpGaD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—KIT—sarcoma	6.38e-05	0.00232	CbGpPWpGaD
Mitoxantrone—Hypotension—Vincristine—sarcoma	6.36e-05	0.00124	CcSEcCtD
Mitoxantrone—Feeling abnormal—Thiotepa—sarcoma	6.33e-05	0.00123	CcSEcCtD
Mitoxantrone—Hyponatraemia—Epirubicin—sarcoma	6.32e-05	0.00123	CcSEcCtD
Mitoxantrone—Renal failure acute—Doxorubicin—sarcoma	6.31e-05	0.00123	CcSEcCtD
Mitoxantrone—Gastrointestinal haemorrhage—Epirubicin—sarcoma	6.29e-05	0.00123	CcSEcCtD
Mitoxantrone—Feeling abnormal—Dactinomycin—sarcoma	6.28e-05	0.00122	CcSEcCtD
Mitoxantrone—Gastrointestinal pain—Thiotepa—sarcoma	6.28e-05	0.00122	CcSEcCtD
Mitoxantrone—Ill-defined disorder—Etoposide—sarcoma	6.27e-05	0.00122	CcSEcCtD
Mitoxantrone—BTK—Activated TLR4 signalling—JUN—sarcoma	6.25e-05	0.00227	CbGpPWpGaD
Mitoxantrone—Anaemia—Etoposide—sarcoma	6.25e-05	0.00122	CcSEcCtD
Mitoxantrone—Gastrointestinal pain—Dactinomycin—sarcoma	6.23e-05	0.00122	CcSEcCtD
Mitoxantrone—BTK—Adaptive Immune System—CD34—sarcoma	6.22e-05	0.00226	CbGpPWpGaD
Mitoxantrone—Musculoskeletal discomfort—Vincristine—sarcoma	6.21e-05	0.00121	CcSEcCtD
Mitoxantrone—Paraesthesia—Vincristine—sarcoma	6.12e-05	0.00119	CcSEcCtD
Mitoxantrone—Urticaria—Thiotepa—sarcoma	6.1e-05	0.00119	CcSEcCtD
Mitoxantrone—Malaise—Etoposide—sarcoma	6.1e-05	0.00119	CcSEcCtD
Mitoxantrone—Body temperature increased—Thiotepa—sarcoma	6.07e-05	0.00118	CcSEcCtD
Mitoxantrone—Abdominal pain—Thiotepa—sarcoma	6.07e-05	0.00118	CcSEcCtD
Mitoxantrone—BTK—DAP12 interactions—CREB1—sarcoma	6.07e-05	0.0022	CbGpPWpGaD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—CREB1—sarcoma	6.07e-05	0.0022	CbGpPWpGaD
Mitoxantrone—Leukopenia—Etoposide—sarcoma	6.05e-05	0.00118	CcSEcCtD
Mitoxantrone—ABCB1—uterus—sarcoma	6.04e-05	0.00305	CbGeAlD
Mitoxantrone—Abdominal pain—Dactinomycin—sarcoma	6.03e-05	0.00118	CcSEcCtD
Mitoxantrone—Body temperature increased—Dactinomycin—sarcoma	6.03e-05	0.00118	CcSEcCtD
Mitoxantrone—Anaphylactoid reaction—Doxorubicin—sarcoma	6.02e-05	0.00117	CcSEcCtD
Mitoxantrone—BTK—BCR signaling pathway—HRAS—sarcoma	5.99e-05	0.00218	CbGpPWpGaD
Mitoxantrone—Cardiac failure—Doxorubicin—sarcoma	5.97e-05	0.00116	CcSEcCtD
Mitoxantrone—Decreased appetite—Vincristine—sarcoma	5.92e-05	0.00115	CcSEcCtD
Mitoxantrone—BTK—B Cell Activation—KIT—sarcoma	5.9e-05	0.00214	CbGpPWpGaD
Mitoxantrone—Cough—Etoposide—sarcoma	5.9e-05	0.00115	CcSEcCtD
Mitoxantrone—Blood creatinine increased—Epirubicin—sarcoma	5.9e-05	0.00115	CcSEcCtD
Mitoxantrone—BTK—Toll Like Receptor 4 (TLR4) Cascade—JUN—sarcoma	5.88e-05	0.00214	CbGpPWpGaD
Mitoxantrone—Fatigue—Vincristine—sarcoma	5.87e-05	0.00114	CcSEcCtD
Mitoxantrone—Convulsion—Etoposide—sarcoma	5.86e-05	0.00114	CcSEcCtD
Mitoxantrone—CYP3A4—liver—sarcoma	5.86e-05	0.00296	CbGeAlD
Mitoxantrone—Dehydration—Epirubicin—sarcoma	5.85e-05	0.00114	CcSEcCtD
Mitoxantrone—Hyponatraemia—Doxorubicin—sarcoma	5.85e-05	0.00114	CcSEcCtD
Mitoxantrone—Hypertension—Etoposide—sarcoma	5.84e-05	0.00114	CcSEcCtD
Mitoxantrone—Constipation—Vincristine—sarcoma	5.82e-05	0.00114	CcSEcCtD
Mitoxantrone—Pain—Vincristine—sarcoma	5.82e-05	0.00114	CcSEcCtD
Mitoxantrone—Gastrointestinal haemorrhage—Doxorubicin—sarcoma	5.82e-05	0.00114	CcSEcCtD
Mitoxantrone—TOP2A—Retinoblastoma (RB) in Cancer—MDM2—sarcoma	5.76e-05	0.00209	CbGpPWpGaD
Mitoxantrone—Chest pain—Etoposide—sarcoma	5.76e-05	0.00112	CcSEcCtD
Mitoxantrone—Abdominal pain upper—Epirubicin—sarcoma	5.75e-05	0.00112	CcSEcCtD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor Pathway—IL2—sarcoma	5.74e-05	0.00209	CbGpPWpGaD
Mitoxantrone—Hypokalaemia—Epirubicin—sarcoma	5.73e-05	0.00112	CcSEcCtD
Mitoxantrone—Discomfort—Etoposide—sarcoma	5.69e-05	0.00111	CcSEcCtD
Mitoxantrone—BTK—B Cell Receptor Signaling Pathway—MYC—sarcoma	5.68e-05	0.00206	CbGpPWpGaD
Mitoxantrone—Aspartate aminotransferase increased—Epirubicin—sarcoma	5.67e-05	0.0011	CcSEcCtD
Mitoxantrone—Hypersensitivity—Thiotepa—sarcoma	5.66e-05	0.0011	CcSEcCtD
Mitoxantrone—ABCG2—HIF-2-alpha transcription factor network—VEGFA—sarcoma	5.65e-05	0.00205	CbGpPWpGaD
Mitoxantrone—ABCB1—lymphoid tissue—sarcoma	5.63e-05	0.00285	CbGeAlD
Mitoxantrone—Hypersensitivity—Dactinomycin—sarcoma	5.62e-05	0.0011	CcSEcCtD
Mitoxantrone—BTK—B Cell Activation—CREB1—sarcoma	5.62e-05	0.00204	CbGpPWpGaD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor Pathway—JUN—sarcoma	5.58e-05	0.00203	CbGpPWpGaD
Mitoxantrone—Gastrointestinal pain—Vincristine—sarcoma	5.57e-05	0.00109	CcSEcCtD
Mitoxantrone—Confusional state—Etoposide—sarcoma	5.56e-05	0.00108	CcSEcCtD
Mitoxantrone—Alanine aminotransferase increased—Epirubicin—sarcoma	5.55e-05	0.00108	CcSEcCtD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—STAG1—sarcoma	5.54e-05	0.00201	CbGpPWpGaD
Mitoxantrone—Anaphylactic shock—Etoposide—sarcoma	5.52e-05	0.00108	CcSEcCtD
Mitoxantrone—Asthenia—Thiotepa—sarcoma	5.51e-05	0.00107	CcSEcCtD
Mitoxantrone—Infection—Etoposide—sarcoma	5.48e-05	0.00107	CcSEcCtD
Mitoxantrone—Asthenia—Dactinomycin—sarcoma	5.47e-05	0.00107	CcSEcCtD
Mitoxantrone—Blood creatinine increased—Doxorubicin—sarcoma	5.45e-05	0.00106	CcSEcCtD
Mitoxantrone—Dehydration—Doxorubicin—sarcoma	5.41e-05	0.00106	CcSEcCtD
Mitoxantrone—Thrombocytopenia—Etoposide—sarcoma	5.4e-05	0.00105	CcSEcCtD
Mitoxantrone—Tachycardia—Etoposide—sarcoma	5.38e-05	0.00105	CcSEcCtD
Mitoxantrone—Body temperature increased—Vincristine—sarcoma	5.38e-05	0.00105	CcSEcCtD
Mitoxantrone—Abdominal pain—Vincristine—sarcoma	5.38e-05	0.00105	CcSEcCtD
Mitoxantrone—Skin disorder—Etoposide—sarcoma	5.36e-05	0.00104	CcSEcCtD
Mitoxantrone—ABCB1—HIF-1-alpha transcription factor network—CXCR4—sarcoma	5.34e-05	0.00194	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 signaling—MDM2—sarcoma	5.34e-05	0.00194	CbGpPWpGaD
Mitoxantrone—Hyperhidrosis—Etoposide—sarcoma	5.33e-05	0.00104	CcSEcCtD
Mitoxantrone—Abdominal pain upper—Doxorubicin—sarcoma	5.32e-05	0.00104	CcSEcCtD
Mitoxantrone—Hypokalaemia—Doxorubicin—sarcoma	5.3e-05	0.00103	CcSEcCtD
Mitoxantrone—BTK—Regulation of toll-like receptor signaling pathway—JUN—sarcoma	5.3e-05	0.00192	CbGpPWpGaD
Mitoxantrone—ABCG2—HIF-1-alpha transcription factor network—CREB1—sarcoma	5.29e-05	0.00192	CbGpPWpGaD
Mitoxantrone—Anorexia—Etoposide—sarcoma	5.26e-05	0.00103	CcSEcCtD
Mitoxantrone—Diarrhoea—Thiotepa—sarcoma	5.26e-05	0.00102	CcSEcCtD
Mitoxantrone—Aspartate aminotransferase increased—Doxorubicin—sarcoma	5.24e-05	0.00102	CcSEcCtD
Mitoxantrone—BTK—Toll-Like Receptors Cascades—JUN—sarcoma	5.24e-05	0.0019	CbGpPWpGaD
Mitoxantrone—Diarrhoea—Dactinomycin—sarcoma	5.22e-05	0.00102	CcSEcCtD
Mitoxantrone—Pancytopenia—Epirubicin—sarcoma	5.17e-05	0.00101	CcSEcCtD
Mitoxantrone—Hypotension—Etoposide—sarcoma	5.16e-05	0.00101	CcSEcCtD
Mitoxantrone—Alanine aminotransferase increased—Doxorubicin—sarcoma	5.14e-05	0.001	CcSEcCtD
Mitoxantrone—ABCB1—bone marrow—sarcoma	5.13e-05	0.00259	CbGeAlD
Mitoxantrone—Neutropenia—Epirubicin—sarcoma	5.09e-05	0.000992	CcSEcCtD
Mitoxantrone—Upper respiratory tract infection—Epirubicin—sarcoma	5.05e-05	0.000986	CcSEcCtD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	5.03e-05	0.00183	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 interactions—MDM2—sarcoma	5.02e-05	0.00182	CbGpPWpGaD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—MDM2—sarcoma	5.02e-05	0.00182	CbGpPWpGaD
Mitoxantrone—TOP2A—Retinoblastoma (RB) in Cancer—CCND1—sarcoma	5.02e-05	0.00182	CbGpPWpGaD
Mitoxantrone—Hypersensitivity—Vincristine—sarcoma	5.02e-05	0.000978	CcSEcCtD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor—SRC—sarcoma	5.01e-05	0.00182	CbGpPWpGaD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor Pathway—SRC—sarcoma	5.01e-05	0.00182	CbGpPWpGaD
Mitoxantrone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRB—sarcoma	5e-05	0.00182	CbGpPWpGaD
Mitoxantrone—Paraesthesia—Etoposide—sarcoma	4.95e-05	0.000966	CcSEcCtD
Mitoxantrone—TOP2A—Cell Cycle—STAG1—sarcoma	4.95e-05	0.0018	CbGpPWpGaD
Mitoxantrone—Weight increased—Epirubicin—sarcoma	4.95e-05	0.000965	CcSEcCtD
Mitoxantrone—Weight decreased—Epirubicin—sarcoma	4.92e-05	0.000959	CcSEcCtD
Mitoxantrone—Dyspnoea—Etoposide—sarcoma	4.92e-05	0.000959	CcSEcCtD
Mitoxantrone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRA—sarcoma	4.92e-05	0.00179	CbGpPWpGaD
Mitoxantrone—Hyperglycaemia—Epirubicin—sarcoma	4.91e-05	0.000957	CcSEcCtD
Mitoxantrone—Somnolence—Etoposide—sarcoma	4.91e-05	0.000956	CcSEcCtD
Mitoxantrone—Asthenia—Vincristine—sarcoma	4.89e-05	0.000953	CcSEcCtD
Mitoxantrone—Vomiting—Thiotepa—sarcoma	4.88e-05	0.000952	CcSEcCtD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor—VEGFA—sarcoma	4.88e-05	0.00177	CbGpPWpGaD
Mitoxantrone—Pneumonia—Epirubicin—sarcoma	4.88e-05	0.000951	CcSEcCtD
Mitoxantrone—Drowsiness—Epirubicin—sarcoma	4.85e-05	0.000946	CcSEcCtD
Mitoxantrone—Vomiting—Dactinomycin—sarcoma	4.85e-05	0.000945	CcSEcCtD
Mitoxantrone—Rash—Thiotepa—sarcoma	4.84e-05	0.000944	CcSEcCtD
Mitoxantrone—Dermatitis—Thiotepa—sarcoma	4.84e-05	0.000943	CcSEcCtD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor—NRAS—sarcoma	4.82e-05	0.00175	CbGpPWpGaD
Mitoxantrone—Headache—Thiotepa—sarcoma	4.81e-05	0.000938	CcSEcCtD
Mitoxantrone—Rash—Dactinomycin—sarcoma	4.81e-05	0.000937	CcSEcCtD
Mitoxantrone—Decreased appetite—Etoposide—sarcoma	4.8e-05	0.000935	CcSEcCtD
Mitoxantrone—Pancytopenia—Doxorubicin—sarcoma	4.78e-05	0.000932	CcSEcCtD
Mitoxantrone—Renal failure—Epirubicin—sarcoma	4.77e-05	0.000929	CcSEcCtD
Mitoxantrone—Fatigue—Etoposide—sarcoma	4.76e-05	0.000927	CcSEcCtD
Mitoxantrone—Jaundice—Epirubicin—sarcoma	4.73e-05	0.000922	CcSEcCtD
Mitoxantrone—Stomatitis—Epirubicin—sarcoma	4.73e-05	0.000922	CcSEcCtD
Mitoxantrone—Constipation—Etoposide—sarcoma	4.72e-05	0.00092	CcSEcCtD
Mitoxantrone—Pain—Etoposide—sarcoma	4.72e-05	0.00092	CcSEcCtD
Mitoxantrone—Urinary tract infection—Epirubicin—sarcoma	4.71e-05	0.000919	CcSEcCtD
Mitoxantrone—Conjunctivitis—Epirubicin—sarcoma	4.71e-05	0.000919	CcSEcCtD
Mitoxantrone—Neutropenia—Doxorubicin—sarcoma	4.71e-05	0.000917	CcSEcCtD
Mitoxantrone—Upper respiratory tract infection—Doxorubicin—sarcoma	4.68e-05	0.000912	CcSEcCtD
Mitoxantrone—Diarrhoea—Vincristine—sarcoma	4.66e-05	0.000909	CcSEcCtD
Mitoxantrone—Sweating—Epirubicin—sarcoma	4.65e-05	0.000906	CcSEcCtD
Mitoxantrone—BTK—B Cell Activation—MDM2—sarcoma	4.65e-05	0.00169	CbGpPWpGaD
Mitoxantrone—Haematuria—Epirubicin—sarcoma	4.62e-05	0.000902	CcSEcCtD
Mitoxantrone—BTK—Innate Immune System—PLCG1—sarcoma	4.58e-05	0.00166	CbGpPWpGaD
Mitoxantrone—Weight increased—Doxorubicin—sarcoma	4.58e-05	0.000893	CcSEcCtD
Mitoxantrone—Nausea—Thiotepa—sarcoma	4.56e-05	0.00089	CcSEcCtD
Mitoxantrone—Weight decreased—Doxorubicin—sarcoma	4.55e-05	0.000888	CcSEcCtD
Mitoxantrone—Sinusitis—Epirubicin—sarcoma	4.55e-05	0.000887	CcSEcCtD
Mitoxantrone—Feeling abnormal—Etoposide—sarcoma	4.55e-05	0.000887	CcSEcCtD
Mitoxantrone—Hyperglycaemia—Doxorubicin—sarcoma	4.54e-05	0.000885	CcSEcCtD
Mitoxantrone—Nausea—Dactinomycin—sarcoma	4.53e-05	0.000883	CcSEcCtD
Mitoxantrone—Agranulocytosis—Epirubicin—sarcoma	4.53e-05	0.000882	CcSEcCtD
Mitoxantrone—Pneumonia—Doxorubicin—sarcoma	4.51e-05	0.00088	CcSEcCtD
Mitoxantrone—Gastrointestinal pain—Etoposide—sarcoma	4.51e-05	0.00088	CcSEcCtD
Mitoxantrone—BTK—Adaptive Immune System—PTPRC—sarcoma	4.5e-05	0.00163	CbGpPWpGaD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor—MYC—sarcoma	4.49e-05	0.00163	CbGpPWpGaD
Mitoxantrone—Drowsiness—Doxorubicin—sarcoma	4.49e-05	0.000875	CcSEcCtD
Mitoxantrone—BTK—B Cell Receptor Signaling Pathway—HRAS—sarcoma	4.46e-05	0.00162	CbGpPWpGaD
Mitoxantrone—Bradycardia—Epirubicin—sarcoma	4.43e-05	0.000864	CcSEcCtD
Mitoxantrone—Renal failure—Doxorubicin—sarcoma	4.41e-05	0.00086	CcSEcCtD
Mitoxantrone—BTK—Adaptive Immune System—PLCG1—sarcoma	4.4e-05	0.0016	CbGpPWpGaD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor—EGFR—sarcoma	4.39e-05	0.00159	CbGpPWpGaD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor Pathway—EGFR—sarcoma	4.39e-05	0.00159	CbGpPWpGaD
Mitoxantrone—ABCB1—testis—sarcoma	4.38e-05	0.00222	CbGeAlD
Mitoxantrone—Urticaria—Etoposide—sarcoma	4.38e-05	0.000855	CcSEcCtD
Mitoxantrone—Haemoglobin—Epirubicin—sarcoma	4.38e-05	0.000853	CcSEcCtD
Mitoxantrone—Stomatitis—Doxorubicin—sarcoma	4.37e-05	0.000853	CcSEcCtD
Mitoxantrone—Jaundice—Doxorubicin—sarcoma	4.37e-05	0.000853	CcSEcCtD
Mitoxantrone—ABCG2—Fluoropyrimidine Activity—TP53—sarcoma	4.37e-05	0.00159	CbGpPWpGaD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—JUN—sarcoma	4.36e-05	0.00159	CbGpPWpGaD
Mitoxantrone—Rhinitis—Epirubicin—sarcoma	4.36e-05	0.000851	CcSEcCtD
Mitoxantrone—Body temperature increased—Etoposide—sarcoma	4.36e-05	0.00085	CcSEcCtD
Mitoxantrone—Abdominal pain—Etoposide—sarcoma	4.36e-05	0.00085	CcSEcCtD
Mitoxantrone—Conjunctivitis—Doxorubicin—sarcoma	4.36e-05	0.00085	CcSEcCtD
Mitoxantrone—Urinary tract infection—Doxorubicin—sarcoma	4.36e-05	0.00085	CcSEcCtD
Mitoxantrone—Hepatitis—Epirubicin—sarcoma	4.35e-05	0.000849	CcSEcCtD
Mitoxantrone—Haemorrhage—Epirubicin—sarcoma	4.35e-05	0.000849	CcSEcCtD
Mitoxantrone—BTK—Innate Immune System—ATF1—sarcoma	4.35e-05	0.00158	CbGpPWpGaD
Mitoxantrone—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	4.34e-05	0.00158	CbGpPWpGaD
Mitoxantrone—Vomiting—Vincristine—sarcoma	4.33e-05	0.000844	CcSEcCtD
Mitoxantrone—Pharyngitis—Epirubicin—sarcoma	4.32e-05	0.000842	CcSEcCtD
Mitoxantrone—Sweating—Doxorubicin—sarcoma	4.3e-05	0.000839	CcSEcCtD
Mitoxantrone—Rash—Vincristine—sarcoma	4.29e-05	0.000837	CcSEcCtD
Mitoxantrone—Dermatitis—Vincristine—sarcoma	4.29e-05	0.000837	CcSEcCtD
Mitoxantrone—Haematuria—Doxorubicin—sarcoma	4.28e-05	0.000834	CcSEcCtD
Mitoxantrone—Headache—Vincristine—sarcoma	4.27e-05	0.000832	CcSEcCtD
Mitoxantrone—TOP2A—Cell Cycle—NPM1—sarcoma	4.25e-05	0.00154	CbGpPWpGaD
Mitoxantrone—Sinusitis—Doxorubicin—sarcoma	4.21e-05	0.000821	CcSEcCtD
Mitoxantrone—CYP2E1—Tryptophan metabolism—MDM2—sarcoma	4.2e-05	0.00152	CbGpPWpGaD
Mitoxantrone—Agranulocytosis—Doxorubicin—sarcoma	4.19e-05	0.000816	CcSEcCtD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor—KRAS—sarcoma	4.15e-05	0.00151	CbGpPWpGaD
Mitoxantrone—ABCB1—liver—sarcoma	4.15e-05	0.00209	CbGeAlD
Mitoxantrone—Bradycardia—Doxorubicin—sarcoma	4.1e-05	0.0008	CcSEcCtD
Mitoxantrone—Hypersensitivity—Etoposide—sarcoma	4.07e-05	0.000793	CcSEcCtD
Mitoxantrone—Haemoglobin—Doxorubicin—sarcoma	4.05e-05	0.000789	CcSEcCtD
Mitoxantrone—Nausea—Vincristine—sarcoma	4.05e-05	0.000789	CcSEcCtD
Mitoxantrone—Rhinitis—Doxorubicin—sarcoma	4.04e-05	0.000787	CcSEcCtD
Mitoxantrone—Hepatitis—Doxorubicin—sarcoma	4.03e-05	0.000785	CcSEcCtD
Mitoxantrone—Haemorrhage—Doxorubicin—sarcoma	4.03e-05	0.000785	CcSEcCtD
Mitoxantrone—TOP2A—Retinoblastoma (RB) in Cancer—MYC—sarcoma	4.03e-05	0.00146	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 signaling—NRAS—sarcoma	4e-05	0.00145	CbGpPWpGaD
Mitoxantrone—Pharyngitis—Doxorubicin—sarcoma	4e-05	0.000779	CcSEcCtD
Mitoxantrone—Asthenia—Etoposide—sarcoma	3.96e-05	0.000772	CcSEcCtD
Mitoxantrone—Chills—Epirubicin—sarcoma	3.91e-05	0.000762	CcSEcCtD
Mitoxantrone—Arrhythmia—Epirubicin—sarcoma	3.89e-05	0.000758	CcSEcCtD
Mitoxantrone—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—sarcoma	3.88e-05	0.00141	CbGpPWpGaD
Mitoxantrone—Alopecia—Epirubicin—sarcoma	3.85e-05	0.00075	CcSEcCtD
Mitoxantrone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—sarcoma	3.81e-05	0.00139	CbGpPWpGaD
Mitoxantrone—ABCG2—HIF-1-alpha transcription factor network—JUN—sarcoma	3.81e-05	0.00138	CbGpPWpGaD
Mitoxantrone—Erythema—Epirubicin—sarcoma	3.79e-05	0.000739	CcSEcCtD
Mitoxantrone—Diarrhoea—Etoposide—sarcoma	3.78e-05	0.000736	CcSEcCtD
Mitoxantrone—BTK—Immune System—CD34—sarcoma	3.77e-05	0.00137	CbGpPWpGaD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—NRAS—sarcoma	3.77e-05	0.00137	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 interactions—NRAS—sarcoma	3.77e-05	0.00137	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	3.71e-05	0.00135	CbGpPWpGaD
Mitoxantrone—Dysgeusia—Epirubicin—sarcoma	3.71e-05	0.000724	CcSEcCtD
Mitoxantrone—Back pain—Epirubicin—sarcoma	3.67e-05	0.000715	CcSEcCtD
Mitoxantrone—BTK—DAP12 signaling—EGFR—sarcoma	3.65e-05	0.00133	CbGpPWpGaD
Mitoxantrone—Chills—Doxorubicin—sarcoma	3.61e-05	0.000705	CcSEcCtD
Mitoxantrone—Arrhythmia—Doxorubicin—sarcoma	3.6e-05	0.000702	CcSEcCtD
Mitoxantrone—Vision blurred—Epirubicin—sarcoma	3.57e-05	0.000696	CcSEcCtD
Mitoxantrone—TOP2A—Circadian rythm related genes—CREB1—sarcoma	3.56e-05	0.0013	CbGpPWpGaD
Mitoxantrone—Alopecia—Doxorubicin—sarcoma	3.56e-05	0.000694	CcSEcCtD
Mitoxantrone—TOP2A—Mitotic G1-G1/S phases—CCND1—sarcoma	3.53e-05	0.00128	CbGpPWpGaD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor—HRAS—sarcoma	3.52e-05	0.00128	CbGpPWpGaD
Mitoxantrone—Ill-defined disorder—Epirubicin—sarcoma	3.52e-05	0.000686	CcSEcCtD
Mitoxantrone—Vomiting—Etoposide—sarcoma	3.51e-05	0.000684	CcSEcCtD
Mitoxantrone—Erythema—Doxorubicin—sarcoma	3.51e-05	0.000684	CcSEcCtD
Mitoxantrone—Anaemia—Epirubicin—sarcoma	3.5e-05	0.000683	CcSEcCtD
Mitoxantrone—BTK—B Cell Activation—NRAS—sarcoma	3.49e-05	0.00127	CbGpPWpGaD
Mitoxantrone—Rash—Etoposide—sarcoma	3.48e-05	0.000678	CcSEcCtD
Mitoxantrone—Dermatitis—Etoposide—sarcoma	3.48e-05	0.000678	CcSEcCtD
Mitoxantrone—Headache—Etoposide—sarcoma	3.46e-05	0.000674	CcSEcCtD
Mitoxantrone—BTK—DAP12 signaling—KRAS—sarcoma	3.45e-05	0.00125	CbGpPWpGaD
Mitoxantrone—Dysgeusia—Doxorubicin—sarcoma	3.43e-05	0.000669	CcSEcCtD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—EGFR—sarcoma	3.43e-05	0.00125	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 interactions—EGFR—sarcoma	3.43e-05	0.00125	CbGpPWpGaD
Mitoxantrone—Malaise—Epirubicin—sarcoma	3.42e-05	0.000666	CcSEcCtD
Mitoxantrone—Leukopenia—Epirubicin—sarcoma	3.39e-05	0.000661	CcSEcCtD
Mitoxantrone—Back pain—Doxorubicin—sarcoma	3.39e-05	0.000661	CcSEcCtD
Mitoxantrone—ABCB1—Allograft Rejection—PDGFRA—sarcoma	3.36e-05	0.00122	CbGpPWpGaD
Mitoxantrone—ABCG2—HIF-1-alpha transcription factor network—VEGFA—sarcoma	3.32e-05	0.00121	CbGpPWpGaD
Mitoxantrone—Cough—Epirubicin—sarcoma	3.31e-05	0.000645	CcSEcCtD
Mitoxantrone—TOP2A—Retinoblastoma (RB) in Cancer—TP53—sarcoma	3.31e-05	0.0012	CbGpPWpGaD
Mitoxantrone—Vision blurred—Doxorubicin—sarcoma	3.3e-05	0.000644	CcSEcCtD
Mitoxantrone—Convulsion—Epirubicin—sarcoma	3.28e-05	0.00064	CcSEcCtD
Mitoxantrone—Nausea—Etoposide—sarcoma	3.28e-05	0.000639	CcSEcCtD
Mitoxantrone—Hypertension—Epirubicin—sarcoma	3.27e-05	0.000638	CcSEcCtD
Mitoxantrone—Ill-defined disorder—Doxorubicin—sarcoma	3.25e-05	0.000634	CcSEcCtD
Mitoxantrone—BTK—Innate Immune System—FOXO1—sarcoma	3.25e-05	0.00118	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—PDGFRB—sarcoma	3.25e-05	0.00118	CbGpPWpGaD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—KRAS—sarcoma	3.24e-05	0.00118	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 interactions—KRAS—sarcoma	3.24e-05	0.00118	CbGpPWpGaD
Mitoxantrone—Anaemia—Doxorubicin—sarcoma	3.24e-05	0.000632	CcSEcCtD
Mitoxantrone—Myalgia—Epirubicin—sarcoma	3.23e-05	0.000629	CcSEcCtD
Mitoxantrone—Chest pain—Epirubicin—sarcoma	3.23e-05	0.000629	CcSEcCtD
Mitoxantrone—Arthralgia—Epirubicin—sarcoma	3.23e-05	0.000629	CcSEcCtD
Mitoxantrone—Anxiety—Epirubicin—sarcoma	3.22e-05	0.000627	CcSEcCtD
Mitoxantrone—BTK—Innate Immune System—PDGFRA—sarcoma	3.19e-05	0.00116	CbGpPWpGaD
Mitoxantrone—Discomfort—Epirubicin—sarcoma	3.19e-05	0.000622	CcSEcCtD
Mitoxantrone—ABCB1—lymph node—sarcoma	3.18e-05	0.00161	CbGeAlD
Mitoxantrone—BTK—B Cell Activation—EGFR—sarcoma	3.18e-05	0.00115	CbGpPWpGaD
Mitoxantrone—Malaise—Doxorubicin—sarcoma	3.16e-05	0.000617	CcSEcCtD
Mitoxantrone—Leukopenia—Doxorubicin—sarcoma	3.14e-05	0.000612	CcSEcCtD
Mitoxantrone—BTK—Adaptive Immune System—FOXO1—sarcoma	3.12e-05	0.00113	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	3.12e-05	0.00113	CbGpPWpGaD
Mitoxantrone—Confusional state—Epirubicin—sarcoma	3.12e-05	0.000608	CcSEcCtD
Mitoxantrone—BTK—Adaptive Immune System—PDGFRB—sarcoma	3.12e-05	0.00113	CbGpPWpGaD
Mitoxantrone—Oedema—Epirubicin—sarcoma	3.09e-05	0.000603	CcSEcCtD
Mitoxantrone—Anaphylactic shock—Epirubicin—sarcoma	3.09e-05	0.000603	CcSEcCtD
Mitoxantrone—Infection—Epirubicin—sarcoma	3.07e-05	0.000599	CcSEcCtD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	3.07e-05	0.00112	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—PDGFRA—sarcoma	3.07e-05	0.00111	CbGpPWpGaD
Mitoxantrone—Cough—Doxorubicin—sarcoma	3.06e-05	0.000597	CcSEcCtD
Mitoxantrone—Shock—Epirubicin—sarcoma	3.04e-05	0.000593	CcSEcCtD
Mitoxantrone—Convulsion—Doxorubicin—sarcoma	3.04e-05	0.000592	CcSEcCtD
Mitoxantrone—Thrombocytopenia—Epirubicin—sarcoma	3.03e-05	0.00059	CcSEcCtD
Mitoxantrone—Hypertension—Doxorubicin—sarcoma	3.03e-05	0.00059	CcSEcCtD
Mitoxantrone—Tachycardia—Epirubicin—sarcoma	3.02e-05	0.000589	CcSEcCtD
Mitoxantrone—Skin disorder—Epirubicin—sarcoma	3e-05	0.000586	CcSEcCtD
Mitoxantrone—BTK—B Cell Activation—KRAS—sarcoma	3e-05	0.00109	CbGpPWpGaD
Mitoxantrone—Hyperhidrosis—Epirubicin—sarcoma	2.99e-05	0.000583	CcSEcCtD
Mitoxantrone—Arthralgia—Doxorubicin—sarcoma	2.99e-05	0.000582	CcSEcCtD
Mitoxantrone—Chest pain—Doxorubicin—sarcoma	2.99e-05	0.000582	CcSEcCtD
Mitoxantrone—Myalgia—Doxorubicin—sarcoma	2.99e-05	0.000582	CcSEcCtD
Mitoxantrone—Anxiety—Doxorubicin—sarcoma	2.97e-05	0.00058	CcSEcCtD
Mitoxantrone—Discomfort—Doxorubicin—sarcoma	2.95e-05	0.000575	CcSEcCtD
Mitoxantrone—Anorexia—Epirubicin—sarcoma	2.95e-05	0.000575	CcSEcCtD
Mitoxantrone—BTK—DAP12 signaling—HRAS—sarcoma	2.93e-05	0.00106	CbGpPWpGaD
Mitoxantrone—Hypotension—Epirubicin—sarcoma	2.89e-05	0.000563	CcSEcCtD
Mitoxantrone—Confusional state—Doxorubicin—sarcoma	2.89e-05	0.000563	CcSEcCtD
Mitoxantrone—Oedema—Doxorubicin—sarcoma	2.86e-05	0.000558	CcSEcCtD
Mitoxantrone—Anaphylactic shock—Doxorubicin—sarcoma	2.86e-05	0.000558	CcSEcCtD
Mitoxantrone—ABCB1—HIF-1-alpha transcription factor network—CREB1—sarcoma	2.86e-05	0.00104	CbGpPWpGaD
Mitoxantrone—Infection—Doxorubicin—sarcoma	2.84e-05	0.000554	CcSEcCtD
Mitoxantrone—TOP2A—Mitotic G1-G1/S phases—MYC—sarcoma	2.83e-05	0.00103	CbGpPWpGaD
Mitoxantrone—Musculoskeletal discomfort—Epirubicin—sarcoma	2.82e-05	0.000549	CcSEcCtD
Mitoxantrone—Shock—Doxorubicin—sarcoma	2.82e-05	0.000549	CcSEcCtD
Mitoxantrone—Thrombocytopenia—Doxorubicin—sarcoma	2.8e-05	0.000546	CcSEcCtD
Mitoxantrone—Tachycardia—Doxorubicin—sarcoma	2.79e-05	0.000545	CcSEcCtD
Mitoxantrone—Skin disorder—Doxorubicin—sarcoma	2.78e-05	0.000542	CcSEcCtD
Mitoxantrone—Paraesthesia—Epirubicin—sarcoma	2.78e-05	0.000541	CcSEcCtD
Mitoxantrone—Hyperhidrosis—Doxorubicin—sarcoma	2.77e-05	0.000539	CcSEcCtD
Mitoxantrone—Dyspnoea—Epirubicin—sarcoma	2.76e-05	0.000538	CcSEcCtD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—HRAS—sarcoma	2.76e-05	0.001	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 interactions—HRAS—sarcoma	2.76e-05	0.001	CbGpPWpGaD
Mitoxantrone—Somnolence—Epirubicin—sarcoma	2.75e-05	0.000536	CcSEcCtD
Mitoxantrone—Anorexia—Doxorubicin—sarcoma	2.73e-05	0.000532	CcSEcCtD
Mitoxantrone—BTK—Immune System—PTPRC—sarcoma	2.73e-05	0.000991	CbGpPWpGaD
Mitoxantrone—Dyspepsia—Epirubicin—sarcoma	2.72e-05	0.000531	CcSEcCtD
Mitoxantrone—Decreased appetite—Epirubicin—sarcoma	2.69e-05	0.000524	CcSEcCtD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	2.68e-05	0.000972	CbGpPWpGaD
Mitoxantrone—Hypotension—Doxorubicin—sarcoma	2.67e-05	0.000521	CcSEcCtD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	2.67e-05	0.00097	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—PLCG1—sarcoma	2.67e-05	0.00097	CbGpPWpGaD
Mitoxantrone—Fatigue—Epirubicin—sarcoma	2.67e-05	0.00052	CcSEcCtD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	2.65e-05	0.000963	CbGpPWpGaD
Mitoxantrone—Constipation—Epirubicin—sarcoma	2.64e-05	0.000516	CcSEcCtD
Mitoxantrone—Pain—Epirubicin—sarcoma	2.64e-05	0.000516	CcSEcCtD
Mitoxantrone—Musculoskeletal discomfort—Doxorubicin—sarcoma	2.61e-05	0.000508	CcSEcCtD
Mitoxantrone—Paraesthesia—Doxorubicin—sarcoma	2.57e-05	0.000501	CcSEcCtD
Mitoxantrone—TOP2A—Circadian rythm related genes—JUN—sarcoma	2.56e-05	0.000931	CbGpPWpGaD
Mitoxantrone—Dyspnoea—Doxorubicin—sarcoma	2.55e-05	0.000497	CcSEcCtD
Mitoxantrone—BTK—B Cell Activation—HRAS—sarcoma	2.55e-05	0.000926	CbGpPWpGaD
Mitoxantrone—Feeling abnormal—Epirubicin—sarcoma	2.55e-05	0.000497	CcSEcCtD
Mitoxantrone—Somnolence—Doxorubicin—sarcoma	2.54e-05	0.000496	CcSEcCtD
Mitoxantrone—BTK—Immune System—ATF1—sarcoma	2.54e-05	0.000921	CbGpPWpGaD
Mitoxantrone—Gastrointestinal pain—Epirubicin—sarcoma	2.53e-05	0.000493	CcSEcCtD
Mitoxantrone—Dyspepsia—Doxorubicin—sarcoma	2.52e-05	0.000491	CcSEcCtD
Mitoxantrone—Decreased appetite—Doxorubicin—sarcoma	2.49e-05	0.000485	CcSEcCtD
Mitoxantrone—BTK—Innate Immune System—KIT—sarcoma	2.48e-05	0.0009	CbGpPWpGaD
Mitoxantrone—Fatigue—Doxorubicin—sarcoma	2.47e-05	0.000481	CcSEcCtD
Mitoxantrone—Urticaria—Epirubicin—sarcoma	2.46e-05	0.000479	CcSEcCtD
Mitoxantrone—Constipation—Doxorubicin—sarcoma	2.45e-05	0.000477	CcSEcCtD
Mitoxantrone—Pain—Doxorubicin—sarcoma	2.45e-05	0.000477	CcSEcCtD
Mitoxantrone—Body temperature increased—Epirubicin—sarcoma	2.44e-05	0.000477	CcSEcCtD
Mitoxantrone—Abdominal pain—Epirubicin—sarcoma	2.44e-05	0.000477	CcSEcCtD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	2.4e-05	0.00087	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—KIT—sarcoma	2.38e-05	0.000864	CbGpPWpGaD
Mitoxantrone—Feeling abnormal—Doxorubicin—sarcoma	2.36e-05	0.00046	CcSEcCtD
Mitoxantrone—BTK—Innate Immune System—CREB1—sarcoma	2.36e-05	0.000857	CbGpPWpGaD
Mitoxantrone—Gastrointestinal pain—Doxorubicin—sarcoma	2.34e-05	0.000456	CcSEcCtD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	2.33e-05	0.000848	CbGpPWpGaD
Mitoxantrone—Hypersensitivity—Epirubicin—sarcoma	2.28e-05	0.000444	CcSEcCtD
Mitoxantrone—Urticaria—Doxorubicin—sarcoma	2.27e-05	0.000443	CcSEcCtD
Mitoxantrone—BTK—Adaptive Immune System—CREB1—sarcoma	2.26e-05	0.000823	CbGpPWpGaD
Mitoxantrone—Body temperature increased—Doxorubicin—sarcoma	2.26e-05	0.000441	CcSEcCtD
Mitoxantrone—Abdominal pain—Doxorubicin—sarcoma	2.26e-05	0.000441	CcSEcCtD
Mitoxantrone—Asthenia—Epirubicin—sarcoma	2.22e-05	0.000433	CcSEcCtD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	2.15e-05	0.00078	CbGpPWpGaD
Mitoxantrone—Diarrhoea—Epirubicin—sarcoma	2.12e-05	0.000413	CcSEcCtD
Mitoxantrone—Hypersensitivity—Doxorubicin—sarcoma	2.11e-05	0.000411	CcSEcCtD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	2.1e-05	0.000763	CbGpPWpGaD
Mitoxantrone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—sarcoma	2.1e-05	0.000762	CbGpPWpGaD
Mitoxantrone—ABCB1—HIF-1-alpha transcription factor network—JUN—sarcoma	2.06e-05	0.000747	CbGpPWpGaD
Mitoxantrone—Asthenia—Doxorubicin—sarcoma	2.05e-05	0.0004	CcSEcCtD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	1.98e-05	0.000721	CbGpPWpGaD
Mitoxantrone—Vomiting—Epirubicin—sarcoma	1.97e-05	0.000383	CcSEcCtD
Mitoxantrone—Diarrhoea—Doxorubicin—sarcoma	1.96e-05	0.000382	CcSEcCtD
Mitoxantrone—BTK—Innate Immune System—MDM2—sarcoma	1.95e-05	0.000709	CbGpPWpGaD
Mitoxantrone—Rash—Epirubicin—sarcoma	1.95e-05	0.00038	CcSEcCtD
Mitoxantrone—Dermatitis—Epirubicin—sarcoma	1.95e-05	0.00038	CcSEcCtD
Mitoxantrone—CYP3A4—Tryptophan metabolism—MDM2—sarcoma	1.95e-05	0.000707	CbGpPWpGaD
Mitoxantrone—Headache—Epirubicin—sarcoma	1.94e-05	0.000378	CcSEcCtD
Mitoxantrone—BTK—Immune System—FOXO1—sarcoma	1.89e-05	0.000688	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—PDGFRB—sarcoma	1.89e-05	0.000687	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—MDM2—sarcoma	1.87e-05	0.000681	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—PDGFRA—sarcoma	1.86e-05	0.000676	CbGpPWpGaD
Mitoxantrone—Nausea—Epirubicin—sarcoma	1.84e-05	0.000358	CcSEcCtD
Mitoxantrone—ABCB1—Allograft Rejection—IL2—sarcoma	1.83e-05	0.000665	CbGpPWpGaD
Mitoxantrone—Vomiting—Doxorubicin—sarcoma	1.82e-05	0.000355	CcSEcCtD
Mitoxantrone—Rash—Doxorubicin—sarcoma	1.8e-05	0.000352	CcSEcCtD
Mitoxantrone—Dermatitis—Doxorubicin—sarcoma	1.8e-05	0.000351	CcSEcCtD
Mitoxantrone—ABCB1—HIF-1-alpha transcription factor network—VEGFA—sarcoma	1.8e-05	0.000653	CbGpPWpGaD
Mitoxantrone—Headache—Doxorubicin—sarcoma	1.79e-05	0.00035	CcSEcCtD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	1.76e-05	0.00064	CbGpPWpGaD
Mitoxantrone—Nausea—Doxorubicin—sarcoma	1.7e-05	0.000331	CcSEcCtD
Mitoxantrone—BTK—Innate Immune System—JUN—sarcoma	1.7e-05	0.000616	CbGpPWpGaD
Mitoxantrone—TOP2A—Circadian rythm related genes—TP53—sarcoma	1.69e-05	0.000615	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—CTNNB1—sarcoma	1.68e-05	0.000611	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—TLE1—sarcoma	1.67e-05	0.000608	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	1.66e-05	0.000602	CbGpPWpGaD
Mitoxantrone—ABCB1—Allograft Rejection—VEGFA—sarcoma	1.56e-05	0.000566	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—SRC—sarcoma	1.52e-05	0.000553	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—NPM1—sarcoma	1.51e-05	0.000548	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—NRAS—sarcoma	1.46e-05	0.000532	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—SRC—sarcoma	1.46e-05	0.000531	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—KIT—sarcoma	1.44e-05	0.000524	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—NRAS—sarcoma	1.41e-05	0.000511	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—CREB1—sarcoma	1.37e-05	0.000499	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—EGFR—sarcoma	1.33e-05	0.000484	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—MDM2—sarcoma	1.33e-05	0.000483	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—ENO2—sarcoma	1.31e-05	0.000475	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—CCND1—sarcoma	1.3e-05	0.000471	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—EGFR—sarcoma	1.28e-05	0.000465	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—KRAS—sarcoma	1.26e-05	0.000458	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	1.22e-05	0.000444	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—KRAS—sarcoma	1.21e-05	0.000439	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—CCND1—sarcoma	1.16e-05	0.000421	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—MDM2—sarcoma	1.14e-05	0.000413	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—PLCG1—sarcoma	1.11e-05	0.000403	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—ENO2—sarcoma	1.09e-05	0.000398	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—HBA1—sarcoma	1.09e-05	0.000395	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—HRAS—sarcoma	1.07e-05	0.000389	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—CXCR4—sarcoma	1.07e-05	0.000387	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—ENO2—sarcoma	1.06e-05	0.000385	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—HBA1—sarcoma	1.05e-05	0.000382	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—MYC—sarcoma	1.04e-05	0.000378	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—HRAS—sarcoma	1.03e-05	0.000374	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—IL2—sarcoma	1.02e-05	0.000369	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	1.01e-05	0.000368	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—JUN—sarcoma	9.88e-06	0.000359	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—CTNNB1—sarcoma	9.8e-06	0.000356	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—ENO2—sarcoma	9.63e-06	0.00035	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—HBA1—sarcoma	9.57e-06	0.000348	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—MYC—sarcoma	9.29e-06	0.000338	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—PLCG1—sarcoma	9.29e-06	0.000337	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—PLCG1—sarcoma	8.98e-06	0.000326	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—SRC—sarcoma	8.86e-06	0.000322	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	8.81e-06	0.00032	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	8.79e-06	0.000319	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	8.73e-06	0.000317	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—NRAS—sarcoma	8.52e-06	0.00031	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—PLCG1—sarcoma	8.17e-06	0.000297	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	7.89e-06	0.000287	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—FOXO1—sarcoma	7.87e-06	0.000286	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—PDGFRB—sarcoma	7.85e-06	0.000285	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—EGFR—sarcoma	7.77e-06	0.000282	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—PDGFRA—sarcoma	7.73e-06	0.000281	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	7.68e-06	0.000279	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—TP53—sarcoma	7.63e-06	0.000277	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—KRAS—sarcoma	7.34e-06	0.000267	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	7.07e-06	0.000257	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—ENO2—sarcoma	6.91e-06	0.000251	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	6.91e-06	0.000251	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—HBA1—sarcoma	6.87e-06	0.00025	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	6.53e-06	0.000237	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—HRAS—sarcoma	6.24e-06	0.000227	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—KIT—sarcoma	6e-06	0.000218	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—PLCG1—sarcoma	5.87e-06	0.000213	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	5.8e-06	0.000211	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—CREB1—sarcoma	5.71e-06	0.000207	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—ENO2—sarcoma	5.21e-06	0.000189	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—HBA1—sarcoma	5.17e-06	0.000188	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—MDM2—sarcoma	4.72e-06	0.000172	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—PLCG1—sarcoma	4.42e-06	0.000161	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—CTNNB1—sarcoma	4.07e-06	0.000148	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—SRC—sarcoma	3.68e-06	0.000134	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—NRAS—sarcoma	3.54e-06	0.000129	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—MYC—sarcoma	3.3e-06	0.00012	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—EGFR—sarcoma	3.23e-06	0.000117	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—ENO2—sarcoma	3.21e-06	0.000117	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—HBA1—sarcoma	3.19e-06	0.000116	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—KRAS—sarcoma	3.05e-06	0.000111	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—PLCG1—sarcoma	2.72e-06	9.89e-05	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—HRAS—sarcoma	2.59e-06	9.41e-05	CbGpPWpGaD
